Mirian Christian, Skyrman Simon, Bartek Jiri, Jensen Lasse Rehné, Kihlström Lars, Förander Petter, Orrego Abiel, Mathiesen Tiit
Department of Neurosurgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
Neurosurgery. 2020 Nov 16;87(6):1289-1298. doi: 10.1093/neuros/nyaa226.
There are examples of incongruence between the WHO grade and clinical course in meningioma patients. This incongruence between WHO grade and recurrence has led to search for other prognostic histological markers.
To study the correlation between the Ki-67 proliferative index (PI), risk of recurrence, and recurrence rates in meningioma patients.
We prospectively collected pathological diagnosis of de novo consecutive meningiomas. In total, we followed 159 patients with clinical controls until recurrence, death, or emigration. We estimated the correlation between risk of recurrence and Ki-67 PI when adjusted for age at diagnosis, sex, WHO grade, extent of surgical resection, and tumor location. We estimated the cumulative incidence of recurrence when considering death without recurrence a competing risk. We report recurrence rates per 100 person-years.
A 1%-point increase of Ki-67 PI yielded a hazard ratio of 1.12 (95% CI: 1.01-1.24) in a multivariate analysis. The cumulative incidence of recurrence was 3% for Ki-67 0% to 4% vs 19% for Ki-67 > 4% meningiomas after 1 yr, but 24% vs 35%, respectively, after 10 yr. There was no significant difference in mean Ki-67 PI between nonrecurrent and recurrent meningioma in a 2-sample t-test (P = .08). The strongest relationship was detected between Ki-67 PI and time to recurrence: Ki-67 < 4% meningiomas recurred after median 4.8 yr, compared to 0.60 to 0.75 yr for patients with higher Ki-67 PI.
Ki-67 PI was a marker for time to recurrence rather than a predictor of recurrence. Ki-67 PI may be utilized for patient tailored follow-up.
在脑膜瘤患者中,世界卫生组织(WHO)分级与临床病程之间存在不一致的情况。WHO分级与复发之间的这种不一致促使人们寻找其他预后组织学标志物。
研究脑膜瘤患者中Ki-67增殖指数(PI)、复发风险和复发率之间的相关性。
我们前瞻性地收集了初发连续性脑膜瘤的病理诊断结果。总共对159例患者进行了临床对照随访,直至复发、死亡或移民。在对诊断时的年龄、性别、WHO分级、手术切除范围和肿瘤位置进行校正后,我们估计了复发风险与Ki-67 PI之间的相关性。在将无复发死亡视为竞争风险的情况下,我们估计了复发的累积发生率。我们报告每100人年的复发率。
在多变量分析中,Ki-67 PI每增加1个百分点,风险比为1.12(95%置信区间:1.01-1.24)。Ki-67为0%至4%的脑膜瘤1年后复发的累积发生率为3%,而Ki-67>4%的脑膜瘤为19%,但10年后分别为24%和35%。在双样本t检验中,非复发性和复发性脑膜瘤的平均Ki-67 PI无显著差异(P = 0.08)。在Ki-67 PI与复发时间之间检测到最强的关系:Ki-67<4%的脑膜瘤中位复发时间为4.8年,而Ki-67 PI较高的患者为0.60至0.75年。
Ki-67 PI是复发时间的标志物,而非复发的预测指标。Ki-67 PI可用于为患者量身定制随访方案。